Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Isosorbide”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,189 records · Page 66Linked to original sources

Antianginal efficacy and tolerability of 50 mg sustained-release isosorbide 5-mononitrate in an open twelve-month observation study.

Thirty-eight male patients with coronary heart disease were treated with 1 capsule Elantan Long (50 mg IS 5-MN) daily over a period of 1 year. Both before and after the 12-month therapy, a placebo phase of 1 week each was carried out. Two hours after drug administration (Elantan Long and placebo, respectively) a standardized exercise test was carried out at the end of each placebo period and every 3 months during the treatment with Elantan Long. Furthermore, anginal attacks and nitroglycerin consumption were recorded throughout the whole study. Under individually maximum comparable load of 81 +/- 20 W, mean ST-segment depression decreased from 0.19 mV (baseline value) to 0.05 mV respectively, after 12 months of therapy, a decrease of 73% (p less than 0.001). The measurement during the last placebo phase with an increase of ST-segment depression up to 0.18 mV still remained slightly below the baseline value. The incidence of anginal attacks highly significantly decreased from 8.4 +/- 2.0 to 2.0 +/- 1.2 attacks/week after 12 months' treatment (p less than 0.001). Correspondingly, additional nitroglycerin consumption also diminished by 76%. Both values increased to 7.1 +/- 1.9 after the following placebo phase. With the exception of 2 cases the tolerability was judged to be 'very good' and 'good'. During long-term therapy with Elantan Long, no sign of tolerance development was found; on the contrary, a further increase in efficacy was seen in the course of therapy.

Adult↗